Shares of Eli Lilly (LLY) were higher Tuesday after the drug manufacturing company announced that starting January first of next year, customers will be able to purchase insulin at a discount of up to 40% amid a partnership with Express Scripts (ESRX) . The deal is intended to help people who have no insurance or high deductible plans. Users can use the Blink Health online pharmacy platform to activate the discounts. The vice president of Lilly Diabetes, said that, "this platform will effectively allow Lilly to lower our insulin retail prices for users of this platform while not affecting the reimbursement system for other people living with diabetes." TheStreet's Alicia McElhaney highlights that Eli Lilly's pricing change comes amid the backlash Mylan (MYL) faced, when it hiked its EpiPen drug earlier this year.
More from Video
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.